Large placebo-controlled studies, which included patients with DKD or non-diabetic patients with CKD, proved the efficacy of SGLT-2 inhibitors [44] and glucagon-like peptide 1 (GLP-1) analogs [45] in decreasing the risk of kidney failure and/or cardiovascular death. This evidence concerns the gene SLC5A2 and diabetic kidney disease.